Table II.
Univariate and multivariate analysis contributing to overall survival.
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
|
|
|
|||
| Variables at initial treatment | No. | P-valuea | Hazard ratio (95% CI) | P-valueb |
| Gender (male vs. female) | 49/25 | 0.572 | ||
| Age (years) (≥60 vs. <60) | 43/31 | 0.910 | ||
| HCC stage (I or II vs. III) | 59/15 | 0.131 | 0.143 (0.009–2.327) | 0.172 |
| Maximum tumor size (cm) (≥2.5 vs. <2.5) | 32/42 | 0.927 | ||
| Tumor number (single vs. multiple) | 23/51 | 0.096 | 0.777 (0.078–7.776) | 0.830 |
| Liver cirrhosis (yes vs. no) | 41/33 | 0.295 | ||
| HBe antigen (positive vs. negative) | 20/54 | 0.003 | 0.058 (0.005–0.645) | 0.020 |
| HBV DNA (≥105 copies/ml vs. <105 copies/ml) | 35/39 | 0.827 | ||
| AST (IU/l) (≥40 vs. <40) | 34/40 | 0.518 | ||
| ALT (IU/l) (≥40 vs. <40) | 33/41 | 0.170 | 0.305 (0.030–3.125) | 0.317 |
| ALP (IU/l) (≥300 vs. <300) | 40/34 | 0.795 | ||
| GGT (IU/l) (≥50 vs. <50) | 35/39 | 0.607 | ||
| Serum albumin (g/dl) (≥4.2 vs. <4.2) | 33/41 | 0.785 | ||
| Total bilirubin (mg/dl) (≥1.0 vs. <1.0) | 27/47 | 0.686 | ||
| Platelet count (×104/mm3) (≥12 vs. <12) | 37/37 | 0.716 | ||
| Prothrombin time (%) (≥80 vs. <80) | 42/32 | 0.387 | ||
| Serum AFP (ng/ml) (≥20 vs.<20) | 37/37 | 0.555 | ||
| DCP (mAU/ml) (≥30 vs. <30) | 36/38 | 0.719 | ||
| Diabetes mellitus (yes vs. no) | 8/66 | 0.560 | ||
| Body mass index ≥23 kg/m2 (yes vs. no) | 36/38 | 0.183 | 0.100 (0.007–1.485) | 0.094 |
a
Log-rank test;
b
Cox proportional hazard model.
HCC, hepatocellular carcinoma; HBe, hepatitis B e; HBV, hepatitis B virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; GGT, γ-glutamyl transpeptidase; AFP, α-fetoprotein; DCP, des-γ-carboxy prothrombin; CI, confidence interval.